Global Inactivated Vaccines Market was valued at approximately USD 40.67 billion in 2023 and is projected to witness a steady compound annual growth rate (CAGR) of 5.72% during the forecast period from 2024 to 2032. Inactivated vaccines, crafted from pathogens that have been neutralized so they no longer pose a threat of infection, play a pivotal role in modern immunization practices. They provide a safer alternative for individuals with compromised immune systems, such as those with chronic conditions or undergoing treatments that weaken immune function. The primary mechanism of these vaccines is to stimulate an immune response by introducing a deactivated version of the pathogen, ensuring the body can recognize and combat the actual disease if exposed in the future.
The Global Inactivated Vaccines Market growth is significantly driven by the rising incidence of infectious diseases globally and the escalating number of clinical research initiatives focused on developing more efficient and accessible vaccines. Inactivated vaccines require multiple doses to maintain immunity over time, making them integral to long-term disease prevention strategies. Inactivated vaccines offer a robust solution that minimizes potential side effects while delivering effective immunization. In addition, advancements in vaccine development are anticipated to create lucrative opportunities for the market. However, stringent regulatory requirements is going to impede the overall demand for the market during the forecast period 2024-2032.
The key regions considered for the market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America have led the charge in the adoption and development of inactivated vaccines due to a strong healthcare framework and significant investment in healthcare innovation. The ongoing efforts by the U.S. and Canadian governments to bolster their healthcare sectors, especially in the domain of vaccine development, are projected to maintain the dominance of these regions. Meanwhile, emerging markets in Asia-Pacific are also witnessing substantial growth, driven by increased awareness of vaccination and significant advancements in healthcare infrastructure, which are expected to contribute to the market's expansion.
Major market players included in this report are:
Mylan N.V.
Boehringer Ingelheim International GmbH
Merck & Co., Inc.
F. Hoffmann-La Roche AG
Bristol-Myers Squibb Company
Bharat Biotech
Serum Institute of India
GSK plc
Novartis AG
Sanofi S.A.
The detailed segments and sub-segment of the market are explained below:
By Vaccine Type:
Viral Vaccine
Bacterial Vaccine
By Method of Inactivation:
Solvent Detergent Method
Radiation Method
pH Concentration
Others
By Route of Administration:
Oral
Subcutaneous
Intravenous
By End-User:
Hospitals
Specialty Clinics
Homecare Settings
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Middle East & Africa
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market
